Search

Displaying results 4171 - 4180 of 5895 in total
  1. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  2. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  3. Drug

    RCT1100

    go.drugbank.com/drugs/DB18830
    Investigational

    RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]

  4. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.

  5. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.

  6. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.

  7. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate

  8. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene). … Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With

  9. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.

  10. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.